JP2021521104A5 - - Google Patents

Info

Publication number
JP2021521104A5
JP2021521104A5 JP2020554437A JP2020554437A JP2021521104A5 JP 2021521104 A5 JP2021521104 A5 JP 2021521104A5 JP 2020554437 A JP2020554437 A JP 2020554437A JP 2020554437 A JP2020554437 A JP 2020554437A JP 2021521104 A5 JP2021521104 A5 JP 2021521104A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
cycloalkyl
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554437A
Other languages
English (en)
Japanese (ja)
Other versions
JP7383635B2 (ja
JP2021521104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026054 external-priority patent/WO2019195720A1/en
Publication of JP2021521104A publication Critical patent/JP2021521104A/ja
Publication of JP2021521104A5 publication Critical patent/JP2021521104A5/ja
Priority to JP2023190466A priority Critical patent/JP7720376B2/ja
Application granted granted Critical
Publication of JP7383635B2 publication Critical patent/JP7383635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554437A 2018-04-06 2019-04-05 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤 Active JP7383635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023190466A JP7720376B2 (ja) 2018-04-06 2023-11-08 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862654108P 2018-04-06 2018-04-06
US62/654,108 2018-04-06
PCT/US2019/026054 WO2019195720A1 (en) 2018-04-06 2019-04-05 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190466A Division JP7720376B2 (ja) 2018-04-06 2023-11-08 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤

Publications (3)

Publication Number Publication Date
JP2021521104A JP2021521104A (ja) 2021-08-26
JP2021521104A5 true JP2021521104A5 (cg-RX-API-DMAC7.html) 2022-08-09
JP7383635B2 JP7383635B2 (ja) 2023-11-20

Family

ID=68101457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554437A Active JP7383635B2 (ja) 2018-04-06 2019-04-05 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤
JP2023190466A Active JP7720376B2 (ja) 2018-04-06 2023-11-08 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023190466A Active JP7720376B2 (ja) 2018-04-06 2023-11-08 置換されたベンゾフラン、ベンゾピロール、ベンゾチオフェン、及び構造的に関連する補体阻害剤

Country Status (34)

Country Link
US (7) US11021458B2 (cg-RX-API-DMAC7.html)
EP (3) EP3687506B1 (cg-RX-API-DMAC7.html)
JP (2) JP7383635B2 (cg-RX-API-DMAC7.html)
KR (1) KR102936604B1 (cg-RX-API-DMAC7.html)
CN (2) CN112272553B (cg-RX-API-DMAC7.html)
AR (1) AR115033A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019247471B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019183A2 (cg-RX-API-DMAC7.html)
CL (2) CL2020002578A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020013840A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124510T1 (cg-RX-API-DMAC7.html)
DK (2) DK3939658T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092383A1 (cg-RX-API-DMAC7.html)
ES (2) ES2891123T3 (cg-RX-API-DMAC7.html)
FI (1) FI3939658T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241536T1 (cg-RX-API-DMAC7.html)
HU (2) HUE055307T2 (cg-RX-API-DMAC7.html)
IL (2) IL305879B2 (cg-RX-API-DMAC7.html)
LT (2) LT3687506T (cg-RX-API-DMAC7.html)
MA (2) MA57412B1 (cg-RX-API-DMAC7.html)
MD (2) MD3687506T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020010508A (cg-RX-API-DMAC7.html)
PE (1) PE20210398A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551589A1 (cg-RX-API-DMAC7.html)
PL (2) PL3687506T3 (cg-RX-API-DMAC7.html)
PT (2) PT3939658T (cg-RX-API-DMAC7.html)
PY (1) PY1927283A (cg-RX-API-DMAC7.html)
RS (2) RS66185B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008972WA (cg-RX-API-DMAC7.html)
SI (2) SI3687506T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100579T1 (cg-RX-API-DMAC7.html)
TW (1) TWI873092B (cg-RX-API-DMAC7.html)
UY (1) UY38174A (cg-RX-API-DMAC7.html)
WO (1) WO2019195720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
AU2020323532A1 (en) * 2019-07-31 2022-03-03 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral complement Factor D inhibitors
PY2062527A (es) * 2019-10-09 2021-09-23 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
TWI908740B (zh) * 2019-10-09 2025-12-21 美商百歐克斯製藥公司 口服補體因子d抑制劑
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ, インコーポレーテッド 補体因子d媒介障害の処置用のヘテロアリール化合物
AR121715A1 (es) * 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
EP4213832A4 (en) * 2020-09-18 2024-10-16 Merck Sharp & Dohme LLC Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
WO2023066357A1 (zh) * 2021-10-21 2023-04-27 江苏恒瑞医药股份有限公司 稠合环类化合物、其制备方法及其在医药上的应用
AR129422A1 (es) * 2022-05-25 2024-08-21 Univ Leuven Kath Nuevos derivados para tratar trastornos mediados por trpm3
US20260183284A1 (en) * 2022-11-22 2026-07-02 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
WO2024148269A2 (en) * 2023-01-06 2024-07-11 Biocryst Pharmaceuticals, Inc. Oral dosage forms and oral dosing regimens for treatment of complement mediated diseases
KR102925481B1 (ko) * 2023-09-05 2026-02-10 광주과학기술원 신규 화합물 및 이의 건선 치료 용도
CN121969751A (zh) 2023-10-11 2026-05-01 瑞泽恩制药公司 使用补体因子d (cfd)抑制剂治疗黄斑变性
CN119504834B (zh) * 2024-11-21 2025-10-17 南开大学 一种以含硅基团为疏水标签的pd-l1蛋白降解剂及其制备方法、药物组合物和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377387A (en) 1966-12-01 1968-04-09 Purdue Research Foundation Process for preparing nitro compounds by reacting organic amines with ozone
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
IL144032A0 (en) 1999-01-13 2002-04-21 Genentech Inc Serine protease inhibitors
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
AU2007254325B2 (en) * 2006-05-15 2012-05-10 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JP2010502618A (ja) * 2006-08-31 2010-01-28 アリーナ ファーマシューティカルズ, インコーポレイテッド セロトニン5−ht2a受容体のモジュレータとしてのベンゾフラン誘導体
SG11201406973PA (en) 2012-05-04 2014-12-30 Novartis Ag Complement pathway modulators and uses thereof
US9056874B2 (en) * 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN105555766A (zh) * 2013-07-18 2016-05-04 诺华股份有限公司 作为补体因子d抑制剂的氨基甲基-联芳基衍生物及其应用
WO2015025026A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
EP3110419A4 (en) 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
WO2016088082A1 (en) * 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
TWI747873B (zh) * 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
AU2020323532A1 (en) 2019-07-31 2022-03-03 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral complement Factor D inhibitors

Similar Documents

Publication Publication Date Title
JP2013532652A5 (cg-RX-API-DMAC7.html)
IL277787B2 (en) Benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors are converted
JP2024543497A5 (cg-RX-API-DMAC7.html)
JP2008510770A5 (cg-RX-API-DMAC7.html)
JP2015503609A5 (cg-RX-API-DMAC7.html)
JP2014518286A5 (cg-RX-API-DMAC7.html)
JP2022545633A5 (cg-RX-API-DMAC7.html)
JP2018526399A5 (cg-RX-API-DMAC7.html)
IL257545A (en) Transformed amino triazoles are useful as human cytinase inhibitors
HRP20210926T1 (hr) Derivati 1h-indazol-3-karboksamida i povezani spojevi kao inhibitori faktora d za liječenje bolesti karakteriziranih pojačanom djelatnošću sustava komplemenata, kao npr. imunološki poremećaji
JP2018528946A5 (cg-RX-API-DMAC7.html)
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
JP2006505543A5 (cg-RX-API-DMAC7.html)
JP2009526034A5 (cg-RX-API-DMAC7.html)
RU2011113402A (ru) ПИРИДО[5,4d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОЛИФЕРАЦИИ КЛЕТОК
JP2009536650A5 (cg-RX-API-DMAC7.html)
JP2005526076A5 (cg-RX-API-DMAC7.html)
JP2009538321A5 (cg-RX-API-DMAC7.html)
JP2023542949A5 (cg-RX-API-DMAC7.html)
JPWO2023022216A5 (cg-RX-API-DMAC7.html)
JP2023551290A5 (cg-RX-API-DMAC7.html)
JP2009539943A5 (cg-RX-API-DMAC7.html)
JP2003535844A5 (cg-RX-API-DMAC7.html)
JP2021522197A5 (cg-RX-API-DMAC7.html)
JP2025502943A5 (cg-RX-API-DMAC7.html)